ProfileGDS5678 / 1446749_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 41% 41% 40% 40% 42% 41% 40% 40% 41% 41% 40% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9989442
GSM967853U87-EV human glioblastoma xenograft - Control 22.9451341
GSM967854U87-EV human glioblastoma xenograft - Control 32.9504441
GSM967855U87-EV human glioblastoma xenograft - Control 42.8608740
GSM967856U87-EV human glioblastoma xenograft - Control 52.8748340
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0570242
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0101541
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9137840
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.895940
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.923441
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9309541
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8950740
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9499141
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.933841